Phase I evaluation of an epothilone B analog (BMS-247550): clinical findings and molecular correlates

Li Liu, MD

University of Pennsylvania Cancer
Last Modified: May 13, 2001

Presenter: S. Mani
Affiliation: NYU Medical Center, NY

Background:

    The epothilones are naturally occurring antimitotic drugs that share with the taxanes a similar mechanism of action without apparent structural similarity. Some early pre-clinical data demonstrated activity against taxane- sensitive and -resistant tumors,

Materials and Methods:

  • A total of 13 patients with various solid malignancies were included in this phase I study
  • Patients were treated with 1-hour infusion of BMS-247550 once every 3 weeks
  • Five dose levels ranging from 7.4 mg/m2 to 59.2 mg/m2 were evaluated

Results:

  • At dose of 50mg/m2, 50% of patients experienced dose-limiting neutropenia/sepsis
  • Other toxicity include neuropathy, anorexia, and weakness
  • Three patients had subjective responses

Authors' Conclusions

  • The MTD of BMS-247550 was established in this phase I study
  • Clinical response was seen one patient with taxane-refractory breast cancer

Clinical/Scientific Implications:

  • The premominant dose-limiting toxicity of BMS- 247550 is neutropenia
  • Clinical toxicity profile should be validated in large trials
  • The clinical responsiveness will be assessed in phase II trials

ASCO Abstract 269

Saturday | Sunday | Monday | Tuesday

OncoLink ASCO 2001 coverage is provided by an unrestricted educational grant from Amgen

Blogs

Breaking news: Supreme Court votes to uphold Affordable Care Act Subsidies
by Christina Bach, MSW, LCSW, OSW-C
June 26, 2015